晚期非小细胞肺癌4种化疗方案的药物经济学评价  

Pharmacoeconomics evaluation of four different chemotherapy regimens against advanced non small cell lung cancer

作　　者：张媚媚[1] 庞廷媛[1] 高文慧[1] 舒文莹[1] 李佳[1] 林蔚[1] 尹一子[1] 

机构地区：[1]广东省广州医科大学附属肿瘤医院药学部,广东广州510095

出　　处：《中国医院药学杂志》2016年第22期2001-2004,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨晚期非小细胞肺癌不同治疗方案的临床疗效和经济学效果。方法:收集某院2012-2015年99例符合要求的晚期非小细胞肺癌患者,根据不同治疗方法分为4组,用药物经济学对成本与效果进行分析,对4组治疗方案进行回顾性分析。A组:多西他赛+顺铂;B组:多西他赛+卡铂;C组:培美曲塞+顺铂;D组:培美曲塞+卡铂。结果:4组化疗方案的有效率分别为40.54%,31.58%,57.89%,54.17%。化疗一个疗程住院总费用分别为6 307.96元,5 356.51元,11 980.83元,11 387.94元。在B方案的基础上,每增加一个单位效果,A方案、C方案、D方案所需要的成本分别为106.19元,251.78,267.00元。结论:从成本-效果分析,A方案为治疗晚期非小细胞肺癌的较合理的方案。OBJECTIVE Pharmacoeconomics evaluation was performed by cost-effective analysis to provide a basis for selec- ting appropriate chemotherapeutic regimens. METItOI~ A total of 99 patients with advanced non small cell lung cancer were enrolled from a hospital, and divided into four groups according to methods of treatment and analysis by pharmacoeconomic cost-effectiveness method, and retrospective analysis was also applied. Group A, docetaxel combined with cisplatim group B, docetaxel combined with carboplatin; group C, pemetrexed combined with cisplatin group D, pemetrexed combined with car- boplatin. RESULTS Effective rates of four regimes were 40. 54%, 31.58%, 57. 89% and 31.58%, respectively. Costs of che- motherapeutic regimens were 6 307. 96, 5 356. 51, 11 980. 83 and 5 356. 51 yuan, respectively. Based on group B, for each u- nit of efficacy increased, costs in regimen A, C, D were increased 106. 19, 251.78 and 267. 00 yuan respectively. CONCLUSION Regimen B against advanced non small cell lung cancer is more appropriate considering the cost and effect.

关 键 词：晚期非小细胞肺癌 化疗方案 成本-效果分析 

分 类 号：R969[医药卫生—药理学]